These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 37772505)

  • 21. T cell-engaging therapies - BiTEs and beyond.
    Goebeler ME; Bargou RC
    Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibodies for immune cell retargeting against cancer.
    Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
    Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
    Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
    Gauthier L; Morel A; Anceriz N; Rossi B; Blanchard-Alvarez A; Grondin G; Trichard S; Cesari C; Sapet M; Bosco F; Rispaud-Blanc H; Guillot F; Cornen S; Roussel A; Amigues B; Habif G; Caraguel F; Arrufat S; Remark R; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E
    Cell; 2019 Jun; 177(7):1701-1713.e16. PubMed ID: 31155232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tri-specific killer engager: unleashing multi-synergic power against cancer.
    Winidmanokul P; Panya A; Okada S
    Explor Target Antitumor Ther; 2024; 5(2):432-448. PubMed ID: 38745768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
    Lin C; Horwitz ME; Rein LAM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody variable region engineering for improving cancer immunotherapy.
    Lou H; Cao X
    Cancer Commun (Lond); 2022 Sep; 42(9):804-827. PubMed ID: 35822503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
    Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
    MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
    Tapia-Galisteo A; Compte M; Álvarez-Vallina L; Sanz L
    Theranostics; 2023; 13(3):1028-1041. PubMed ID: 36793863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances of bispecific antibodies in solid tumors.
    Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
    J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
    Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
    Front Immunol; 2020; 11():762. PubMed ID: 32457743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
    van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
    Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.